Neoplasm by Morphology — Drugs

Neoplasm by Morphology — Drugs · CancerIndex

Regulatory

Approvals by jurisdiction

500 approval records across 2 jurisdictions, including tumor-agnostic approvals.

openfdaRegulatory5 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Pembrolizumab	US FDA	Urothelial Carcinoma	as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.	approved	Sep 4, 2014	openfda
Pembrolizumab	US FDA	Lung Non-Small Cell Carcinoma	Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.	approved	Sep 4, 2014	openfda
Pembrolizumab	US FDA	Melanoma	for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.	approved	Sep 4, 2014	openfda
Pembrolizumab	US FDA	dMMR Colorectal Carcinoma	Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.	approved	Sep 4, 2014	openfda
Pembrolizumab	US FDA	Hepatocellular Carcinoma	Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.	approved	Sep 4, 2014	openfda

Data updated 2 days agoSource updated unknown

Curated evidence

Therapies appearing in curated evidence

Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.

Therapy	Evidence items (count)	Sensitivity / response	Resistance
Dasatinib	280	157	123
Imatinib	241	134	107
Erlotinib	234	154	80
Crizotinib	207	112	95
Vemurafenib	201	102	98
Gefitinib	157	131	26
Sunitinib	144	82	61
Afatinib	112	105	7
Trametinib	108	94	14
Imatinib Mesylate	97	19	78
Dabrafenib	96	65	31
Bosutinib	90	31	59
Sorafenib

Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.